NCT04488172

Brief Summary

The management of patients with epilepsy is focused on controlling seizures, avoiding treatment side effects, and restoring quality of life. However, about 30% of people are antiepileptic drugs (AEDs) resistance epilepsy after the adequate trials of two AEDs treatment. Genetic factors may contribute to the high interindividual variability in response or adverse effects (such as weight gain and altered lipid profiles) to AEDs. What's more, previous observational studies indicated that vitamin deficiency, such as vitamin B6, is common in patients with epilepsy due to epilepsy itself, AEDs use, or both. Therefore, investigators aim to (1) evaluate the impact of genetic variants on AED and multi-vitamins supplementation in epilepsy, and (2) establish the pharmacogenomics knowledge base of AED and multi-vitamins supplementation on clinical effectiveness in patients with epilepsy.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Apr 2015

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 7, 2015

Completed
5.3 years until next milestone

First Submitted

Initial submission to the registry

July 21, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 27, 2020

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2021

Completed
Last Updated

July 27, 2020

Status Verified

February 1, 2020

Enrollment Period

6.2 years

First QC Date

July 21, 2020

Last Update Submit

July 23, 2020

Conditions

Keywords

pharmacogenomicsantiepileptic drugsmulti-vitamins supplementationepilepsy

Outcome Measures

Primary Outcomes (1)

  • Seizure severity

    Number of seizure attack per month

    6 months

Secondary Outcomes (1)

  • Medication Compliance

    6 months

Study Arms (1)

Epilepsy subjects

EXPERIMENTAL

Receiving multi-vitamins supplementation (B6, B9, D, E, Q10) for 6 months trial

Dietary Supplement: Multi-vitamin supplementation

Interventions

Vitamin B6:100 mg/day Vitamin B9: 5 mg/day Vitamin D: 1000 IU/day Vitamin E: 400 IU/day Co-Q10: 100 mg/day

Epilepsy subjects

Eligibility Criteria

Age20 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnostic criteria of epilepsy
  • Receive anti-epileptic drugs (AEDs)

You may not qualify if:

  • Have an organic mental disorder, mental retardation, dementia, or other diagnosed neurological illness
  • Have a surgical condition or a major physical illness
  • Pregnant or breast-feeding

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Cheng Kung University (NCKU) Hospital

Tainan, Taiwan

RECRUITING

MeSH Terms

Conditions

Epilepsy

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System Diseases

Central Study Contacts

Hui Hua Chang, Ph.D

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 21, 2020

First Posted

July 27, 2020

Study Start

April 7, 2015

Primary Completion

July 1, 2021

Study Completion

July 1, 2021

Last Updated

July 27, 2020

Record last verified: 2020-02

Locations